SCH-12041 |
PAXIPAM |
HALAZEPAM |
ALAPRYL® |
HALAZEPAMUM |
HALAZÉPAM |
rxcui:26412 |
chembl:CHEMBL970 |
chemidplus:23092-17-3 |
pubchem.compound:31640 |
drugbank:00801 |
Drug Class | muscle relaxants |
Drug Class | anti-anxiety agents |
Drug Class | sedative |
Year of Approval | 1981 |
FDA Approval | 1981 |
Drug Class | small molecule |
Drug Indications | Sedative |
Drug Indications | Muscle Relaxants |
Drug Indications | Anti-anxiety Agents |
potentiator |
Trial Name | - |
Novel drug target | Established target |
potentiator |
Trial Name | - |
Novel drug target | Established target |
potentiator |
Novel drug target | Established target |
Trial Name | - |
ligand |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Novel drug target | Established target |
Trial Name | - |
Direct Interaction | yes |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
positive modulator (activating) |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
HALAZEPAM | Primary Drug Name |
Year of Approval | 1981 |
Drug Class | sedative |
Drug Class | anti-anxiety agents |
Drug Indications | Anti-anxiety Agents |
Drug Indications | Muscle Relaxants |
Drug Indications | Sedative |
D0Z9VB | TTD Drug ID |